Results 261 to 270 of about 77,471 (339)

Osteomyelitis: Epidemiology, Classification, Pathophysiology, Clinical Features, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
The immunosuppressive in OM Staphylococcus aureus employs multiple physical barriers to evade host immunity during skeletal infection, including biofilm formation on implant surfaces and necrotic bone tissues, invasion into the osteocyte lacuno‐canalicular network (OLCN), intracellular persistence within osteoblasts, osteoclasts, and osteocytes, and ...
Qingqiang Lei, Liangbin Lin, Peidong Pu, Jie Chen, Xianchao Su, Shubao Liu, Yanli Tong, Hui Yu   +7 more
wiley   +1 more source

PIK3CA NP_006209.2:p.E542X [PDF]

, 2020
openaire   +1 more source

Envonalkib Versus Crizotinib in Treatment‐Naive ALK‐Positive Non‐Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study

MedComm, Volume 7, Issue 10, October 2026.
Envonalkib provides robust and durable benefit in treatment‐naïve ALK‐positive NSCLC, with median PFS of 30.4 months versus 12.0 months for crizotinib. Exploratory biomarker analyses showed that concurrent driver alterations and p53 pathway dysfunction reduce treatment efficacy.
Jie Huang, Yuanyuan Wang, Haishuang Sun, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen, Shouan Ren, Jianying Zhou, Wu Zhuang, Xintian Qin, Lejie Cao, Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu, Lin Zhang, Xinyuan Zhao, Wenfeng Fang, Jing Li, Li Zhang, Yunpeng Yang   +25 more
wiley   +1 more source

Tumor genomic landscape of older patients with metastatic breast cancer^☆. [PDF]

ESMO Open
Gupta H, Brantley KD, Grinda T, Freedman RA, Kodali A, Kirkner GJ, Hughes ME, Higgins A, Newman AB, Avdulla S, Files J, Suggs G, Tolaney SM, Dillon D, Sholl L, Garrido-Castro AC, Cherniack AD, Lin NU.   +17 more
europepmc   +1 more source

PIK3CA NP_006209.2:p.H1047X [PDF]

, 2020
openaire   +1 more source

Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
Colorectal cancer is a heterogeneous, adaptive disease shaped by population‐level risk, genomic and epigenetic alterations, tumor ecosystem evolution, and treatment pressure. This review integrates epidemiology, risk factors, signaling networks, clinical presentation, screening, molecular diagnosis, and stage‐ and biomarker‐guided management while ...
Kairui Wan, Ke Tang, Linglong Wang, Qin Tian, Mingwei Zheng, Cheng Qian, Limei Liu   +6 more
wiley   +1 more source

Case report: Long-term local control of recurrent lymphatic malformations using minocycline sclerotherapy following surgical resection in a dog. [PDF]

Front Vet Sci
Taki H, Sakai T, Kondo T, Yokoyama D, Fujiki J, Yamamoto S, Torisu S.   +6 more
europepmc   +1 more source

PIK3CA Protein Variant [PDF]

, 2020
openaire   +1 more source

KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine

MedComm, Volume 7, Issue 10, October 2026.
KRAS‐mutant cancers are therapeutically shaped by both allele identity and tumor context. Direct KRAS inhibition has achieved the greatest clinical success in KRAS G12C‐mutant NSCLC, whereas colorectal cancer often requires EGFR cotargeting and pancreatic cancer remains constrained by stromal and metabolic barriers. Shared resistance mechanisms include
Jiaying Cai, Yimin Wu, Xing Jia, Li Yang, Wenjun Yang, Weishan Lu, Zhiye Huang, Yang Pan, Zixuan Fei, Junnan Ru, Jiazheng Zhao, Jue Shen, Taobo Luo, Da Chen, Haihong Yu, Haihan Deng, Jian Zeng, Wenmei Jiang, Leilei Wu   +18 more
wiley   +1 more source

PIK3CA NP_006209.2:p.H1047Q [PDF]

, 2020
openaire   +1 more source